



EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomised clinical trials

News 22/03/2021

EMA has reviewed the latest evidence on the use of ivermectin for the prevention and treatment of COVID-19 and concluded that the available data do not support its use for COVID-19 outside well-designed clinical trials.

In the EU, ivermectin tablets are approved for treating some parasitic worm infestations while ivermectin skin preparations are approved for treating skin conditions such as rosacea. Ivermectin is also authorised for veterinary use for a wide range of animal species for internal and external parasites.

Ivermectin medicines are not authorised for use in COVID-19 in the EU, and EMA has not received any application for such use.¹

Following recent media reports and publications on the use of ivermectin, EMA reviewed the latest published evidence from laboratory studies, observational studies, clinical trials and meta-analyses. Laboratory studies found that ivermectin could block replication of SARS-CoV-2 (the virus that causes COVID-19), but at much higher ivermectin concentrations than those achieved with the currently authorised doses. Results from clinical studies were varied, with some studies showing no benefit and others reporting a potential benefit. Most studies EMA reviewed were small and had additional limitations, including different dosing regimens and use of concomitant medications. EMA therefore concluded that the currently available evidence is not sufficient to support the use of ivermectin in COVID-19 outside clinical trials.

Although ivermectin is generally well tolerated at doses authorised for other indications, side effects could increase with the much higher doses that would be needed to obtain concentrations of ivermectin in the lungs that are effective against the virus. Toxicity when ivermectin is used at higher than approved doses therefore cannot be excluded.

EMA therefore concluded that use of ivermectin for prevention or treatment of COVID-19

cannot currently be recommended outside controlled clinical trials. Further well-designed, randomised studies are needed to draw conclusions as to whether the product is effective and safe in the prevention and treatment of COVID-19.

This EMA public health statement has been endorsed by the [COVID-19 EMA pandemic Task Force](#) (COVID-ETF), in light of the ongoing discussions on the use of ivermectin in the prevention and treatment of COVID-19.

¹ [Czechia](#) and [Slovakia](#), have allowed the temporary use of the medicine for COVID-19 within the remit of their national legislation.

References

1. Elgazzar, A., et al., *Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic*. Research Square, 2020.
2. Ahmed, S., et al., *A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness*. Int J Infect Dis, 2021. 103: p. 214-216.
3. Alam, M.T., et al., *Ivermectin as pre-exposure prophylaxis for COVID-19 among healthcare providers in a selected tertiary hospital in Dhaka – an observational study*. European Journal of Medical Health and Sciences, 2020.
4. Arévalo, A.P., et al., *Ivermectin reduces coronavirus infection in vivo: a mouse experimental model*. Biorxiv, 2020.
5. Babalola, O.E., et al., *Ivermectin shows clinical benefits in mild to moderate COVID19: a randomised controlled double-blind, dose-response study in Lagos*. QJM, 2021.
6. Behera, P., et al., *Prophylactic role of ivermectin in SARS-CoV-2 infection among healthcare workers*. Research Square, 2021.
7. Bray, M., et al., *Ivermectin and COVID-19: a report in antiviral research, widespread interest, an FDA warning, two letters to the editor and the authors' responses*. Antiviral Res, 2020. 178: p. 104805.
8. Caly, L., et al., *The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro*. Antiviral Res, 2020. 178: p. 104787.
9. Camprubí, D., et al., *Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients*. PLoS One, 2020. 15(11): p. e0242184.
10. Carvallo, H., et al., *Safety and efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID 19*. MedRxiv, 2020.
11. Carvallo, H., et al., *Study of the efficacy and safety of topical ivermectin + iota-carrageenan in the prophylaxis against COVID-19 in health personnel*. Journal of Biomedical Research and Clinical Investigation, 2020.

12. Castañeda-Sabogal, A., et al., *Outcomes of ivermectin in the treatment of COVID-19: a systematic review and meta-analysis*. Medrxiv, 2021.
13. Chaccour, C., et al., *Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats*. Sci Rep, 2020. 10(1): p. 17073.
14. Chaccour, C., et al., *The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial*. EClinicalMedicine, 2021: p. 100720.
15. Chachar, A.Z.K., et al., *Effectiveness of ivermectin in SARS-CoV-2/COVID-19 patients*. International Journal of Sciences, 2020. 9(09): p. 31-35.
16. Chowdhury, A.T.M.M., et al., *A randomized trial of ivermectin-doxycycline and hydroxychloroquine-azithromycin therapy on COVID19 patients*. Research Square, 2020.
17. de Melo, G.D., et al., *Anti-COVID-19 efficacy of ivermectin in the golden hamster*. BioRxiv, 2020.
18. Elalfy, H., et al., *Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19*. J Med Virol, 2021.
19. Errecalde, J., et al., *Safety and pharmacokinetic assessments of a novel ivermectin nasal spray formulation in a pig model*. J Pharm Sci, 2021.
20. Espitia-Hern, G., et al., *Effects of ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study*. Biomedical Research, 2020.
21. Formiga, F.R., et al., *Ivermectin: an award-winning drug with expected antiviral activity against COVID-19*. J Control Release, 2020.
22. Gonzalez, J.L.B., et al., *Efficacy and safety of ivermectin and hydroxychloroquine in patients with severe COVID-19. A randomized controlled trial*. Medrxiv, 2021.
23. Gorial, F.I., et al., *Effectiveness of ivermectin as add-on therapy in COVID-19 management (pilot trial)*. Medrxiv, 2020.
24. Hashim, H.A., et al., *Controlled randomized clinical trial on using ivermectin with doxycycline for treating COVID-19 patients in Baghdad, Iraq*. Medrxiv, 2020.
25. Hellwig, M.D., and Maia, A., *A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin*. Int J Antimicrob Agents, 2021. 57(1): p. 106248.
26. Hill, A., et al., *Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection*. Research Square, 2021.

27. Jermain, B., et al., *Development of a minimal physiologically-based pharmacokinetic model to simulate lung exposure in humans following oral administration of ivermectin for COVID-19 drug repurposing*. J Pharm Sci, 2020. 109(12): p. 3574-3578.
28. Kalfas, S., et al., *The therapeutic potential of ivermectin for covid-19: a systematic review of mechanisms and evidence*. Medrxiv, 2020.
29. Khan, M.S.I., et al., *Ivermectin treatment may improve the prognosis of patients with COVID-19*. Arch Bronconeumol, 2020. 56(12): p. 828-830.
30. Kim, M.S., et al., *Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: a systematic review and network meta-analysis*. PLoS Med, 2020. 17(12): p. e1003501.
31. Kory, P., et al., *Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19*. FICCC.net, 2021.
32. Krolewiecki, A., *Antiviral effect of high-dose ivermectin in adults with COVID-19: a pilot randomised, controlled, open label, multicentre trial*. Lancet preprint, 2020.
33. Lehrer, S., and Rheinstein, P.H., *Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2*. In Vivo, 2020. 34(5): p. 3023-3026.
34. Lima-Morales, R., et al., *Effectiveness of a multidrug therapy consisting of ivermectin, azithromycin, montelukast and acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico*. Int J Infect Dis, 2021.
35. López-Medina, E., et al., *Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial*. JAMA, 2021.
36. Mittal, N. and Mittal, R., *Inhaled route and anti-inflammatory action of ivermectin: Do they hold promise in fighting against COVID-19?* Med Hypotheses, 2021. 146: p. 110364.
37. Mohan, A., et al., *Ivermectin in mild and moderate COVID-19 (RIVET-COV): a randomized, placebo-controlled trial*. Research Square, 2021.
38. Niaee, M.S., *Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: a randomized multi-center clinical trial*. Research Square, 2020.
39. Okumuş, N., et al., *Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 Patients*. Research Square, 2021.
40. Patel, A., Desai, S., et al, *RETRACTED, Ivermectin in COVID-19 related critical illness*. 2020.
41. Podder, C.S., et al., *Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study*. IMC J Med Sci, 2020.

42. Rajter, J.C., et al., *Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: the ivermectin in covid nineteen study*. Chest, 2021. 159(1): p. 85-92.
43. Ravikirti, R., et al., *Ivermectin as a potential treatment for mild to moderate COVID-19 – a double blind randomized placebo-controlled trial*. Medrxiv, 2021.
44. Bukhari, S.K.H.S., et al., *Efficacy of ivermectin in COVID-19 patients with mild to moderate disease*. Medrxiv, 2021.
45. Soto-Becerra, P., et al., *Real-world effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: results of a target trial emulation using observational data from a nationwide healthcare system in Peru*. Medrxiv, 2020.
46. Spoorthi, V., and Surapaneni, S., *Utility of ivermectin and doxycycline combination for the treatment of SARS-CoV-2*. International Archives of Integrated Medicine, 2020.

Related content

- [Coronavirus disease \(COVID-19\)](#)
- [COVID-19: latest updates](#)
- [Public-health advice during COVID-19 pandemic](#)

External links

- [Trial Site News: Slovakia Becomes the First EU Nation to Formally Approve Ivermectin for Both Prophylaxis and Treatment for COVID-19 Patients](#) [↗](#)
- [Státní ústav pro kontrolu léčiv: Informace o povolení používání neregistrovaného léčivého přípravku HUMEVEC \(ivermektin\)](#) [↗](#)

Contact point

EMA press office

Tel. +31 (0)88 781 8427

E-mail: press@ema.europa.eu

Follow us on Twitter [@EMA_News](#) [↗](#)

CONTACT

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Tel: +31 (0)88 781 6000

For delivery address, see:
How to find us

For the United Kingdom, as of 1 January 2021, European Union law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland / NI.

© 1995-2021 European Medicines Agency

European Union agencies network



An agency of the European Union

